02191naa a2200337 a 450000100080000000500110000800800410001902200140006002400520007410000140012624501490014026000090028930000100029852011230030865300230143165300440145465300320149865300420153070000200157270000180159270000240161070000140163470000190164870000170166770000200168470000240170470000130172870000160174170000180175777300780177521663692024-08-28       2024    bl uuuu     u00u1 u    #d  a1549-96347 ahttps://doi.org/10.1016/j.nano.2024.1027702DOI1 aISLAM, A.  aNanostructured gadolinium(III) micellesbSynthesis, characterization, cytotoxic activities, and MRI applications in vivo.h[electronic resource]  c2024  a1 - 8  aGadolinium-based contrast agents (GBCAs) are used in around 40 % oJ MRI procedures. Despite initial perceptions oJ minimal risk, their long-term use has emphasized the need to reduce toxicity and develop more eJScient GBCAs with extended blood retention. Advancements in nanomaterials have led to improved GBCAs, enhancing MRI diagnostics. This study synthesizes and characterizes nanostructured gadolinium(III) micelles as superior MRI contrast agents. The complexes, [Gd(L)2], where L is a ligand oJ the N-alkyl-N-methylglucamine surJactant series (L8, L10 or L12, L10), Jorm nanostructured micelles in aqueous solution. Gd(L8)2 and Gd(L10)2 relaxivities remained stable across concentrations. Compared to Gd-DTPA, Gd(III) micelles showed enhanced T1-weighted MRI contrast. Gd(L12)2 micelles exhibited cytotoxicity against B16F10 melanoma cells (IC50 42.5 × 2.2 μM) and L292L929 Sbroblasts (IC50 52.0 × 2.5 μM), with a selectivity index oJ 1.2. In vivo application in mice brain T2-weighted images suggests nanostructured Gd(III) micelles are promising MRI contrast agents Jor targeting healthy organs or tumors.  aAntitumor activity  aGadolinium(III) nanostructured micelles  aMethylglucamine surJactants  aN-alkyl-N-methylglucamine surfactants1 aSILVA, S. R. da1 aDUARTE, E. C.1 aTOTARO, P. I. S. de1 aDITTZ, D.1 aCOLNAGO, L. A.1 aPAIVA, F. F.1 aLOPES, M. T. P.1 aMENDES, E. M. A. M.1 aRIAZ, F.1 aFREZARD, F.1 aDEMICHELI, C.  tNanomedicine: Nanotechnology, Biology, and Medicinegv. 62, 102770, 2024.